Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?

Abstract

Objective:

Opioids are among the most effective and potent analgesics currently available. Their utility in the management of pain associated with cancer, acute injury, or surgery is well recognized. However, extending the application of opioids to the management of chronic non-cancer pain has met with considerable resistance. This resistance is due in part to concerns related to gastrointestinal and central nervous system-related adverse events as well as issues pertaining to regulatory affairs, the development of tolerance, incorrect drug usage, and addiction. This review focuses on the incidence of opioid-related side effects and the patient and physician barriers to opioid therapy for chronic non-cancer pain. Tapentadol, a centrally acting analgesic with two mechanisms of action, µ-opioid agonism and norepinephrine reuptake inhibition, may be considered to be a partial solution to some of these issues.

Methods:

MEDLINE was searched for English-language articles from 1950 to February 2010 using the terms chronic non-cancer pain and opioids together and in combination with undertreatment, adherence, and compliance.

Results:

The majority of patients treated with traditional opioids experience gastrointestinal- or central nervous system-related adverse events, most commonly constipation, nausea, and somnolence. These side effects often lead to discontinuation of opioid therapy. Concerns about side effects, analgesic tolerance, dependence, and addiction limit the use of opioids for the management of chronic pain. Treatment with tapentadol appears to provide several advantages of an analgesic with a more favorable side-effect profile than the classic µ-opioid receptor agonist oxycodone (especially related to gastrointestinal tolerability).

Conclusions:

The pervasiveness of opioid-associated side effects and concerns related to tolerance, dependence, and addiction present potential barriers to the approval and use of opioids for the management of chronic non-cancer pain. The lower incidence of opioid-associated adverse events and possibly fewer withdrawal symptoms, combined with a satisfactory analgesic profile associated with tapentadol, suggest its potential utility for the management of chronic non-cancer pain. This review will focus on the incidence of opioid-related side effects and barriers to opioid therapy that are available as English-language articles in the MEDLINE index, and as such, it is a representative but not an exhaustive review of the current literature.

Key words::

• Opioid analgesics
• Refractory pain
• Tapentadol
• Treatment failure

Transparency

Declaration of funding

Tapentadol is manufactured by Johnson & Johnson Pharmaceutical Services, L.L.C.

Declaration of financial/other relationships

The authors were not compensated and retained full editorial control over the content of the manuscript. Peer reviewers may receive honoraria from CMRO for their review work. Peer reviewer 1 has disclosed that he/she is a consultant/advisor to Prime Medica; and is a shareholder in and former employee of AstraZeneca. Peer reviewer 2 has disclosed no relevant financial relationships.

Acknowledgments

Editorial support for the writing of this manuscript was provided by Megan Knagge, PhD, of MedErgy, and was funded by Johnson & Johnson Pharmaceutical Services, L.L.C.